A new study reports that effective management of neonatal abstinence syndrome (NAS) – withdrawal symptoms occurring in infants exposed to opioids in utero – requires a coordinated ‘cascade of care’ from prevention through long-term follow-up.
A new study reports that effective management of neonatal abstinence syndrome (NAS) – withdrawal symptoms occurring in infants exposed to opioids in utero – requires a coordinated ‘cascade of care’ from prevention through long-term follow-up.